Description
Created On: 2020-07-15
Record Count: 3
Primary Industries
- Drugs
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 274841
— an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
— an exclusive sublicense, with rights to sublicense, under all rights granted to License pursuant to another Party License agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
Product means a formulation or composition containing IFN and designated, detailed, or labeled for oral use in the treatment of the Licensed Indications.
Interferons (IFNs) are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.
Competing Product means a product for human use that contains IFN and is marketed, distributed or sold in the Territory that is likely to be confused with or used as a substitute for the Product, such confusion and likelihood of substitution being determined based on an analysis of factors such as, but not limited to, recommended dosage, similarity in indications for which it is marketed, distributed or sold, or similarity in tradedress or trademarks used in the marketing, distribution or sale thereof.
Parties are working together to bring a promising new prevention and treatment option for influenza to the developing world.
IPSCIO Record ID: 248386
(a) an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
(b) an exclusive sublicense, with rights to sublicense, under all rights granted to Licensor pursuant to the HBL Agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
IFN means human interferon alpha.
Licensed Indications means influenza and one other human indication treated or treatable by the oral administration of IFN.
Licensor Technology means the Licensor Patent Rights and the Licensor Know-How. Licensor Patent Rights means all Patent Rights that are under the Control of Licensor as of the Effective Date and at any time during the Term that are necessary or useful to the use, development, Manufacture, marketing, promotion, distribution, sale and/or commercialization of the Product for use in the treatment of the Licensed Indication, and Improvements thereto developed by or on behalf of Licensor during the Term.
IPSCIO Record ID: 248341
(a) an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
(b) an exclusive sublicense, with rights to sublicense, under all rights granted to Licensor pursuant to the HBL Agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
IFN means human interferon alpha. HBL IFN means the cell culture derived human lymphoblastoid IFN produced by HBL.
Licensor Technology means the Licensor Patent Rights and the Licensor Know-How.
Licensor Patent Rights means all Patent Rights that are under the Control of Licensor as of the Effective Date under US patent laws’ protection, and at any time during the term that are necessary or useful to the use, development, Manufacture, marketing, promotion, distribution, sale and/or commercialization of the Product for use in the treatment of the Licensed Indications, and Improvements thereto developed by or on behalf of Licensor during the term.
